ZWI Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ZWI Therapeutics, Inc. - overview
Established
2020
Location
Watertown, MA, US
Primary Industry
Biotechnology
About
Established in 2020 and based in Massachusetts, US, ZWI Therapeutics, Inc. provides therapeutics i. e. novel proteins developed using their zwitterionic polymer technology.
As of 2024, the company is headed by its CEO Ed Mascioli. In January 2024, the firm raised USD 10 million in Series A funding from investors Co-win Ventures and Healthcare Partners. The company offers a superior polymer, polyCarboxyBetaine (pCB) which has physio-chemical properties and helps in reducing immunogenicity. The firm polymer technology helps in the development of nanoparticles.
Moreover, the firm pCB helps in developing hydrogel which has multiple applications such as cellular therapies, etc.
Current Investors
Co-Win Ventures, Sherpa Healthcare Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.zwitx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.